

JAN 13 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/662,165
Filing Date	09/03/2003
First Named Inventor	T. Yasuma
Art Unit	1625
Examiner Name	E. Mei Huang
Attorney Docket Number	2689 US1P

6

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard; Certificate of Express Mailing; Election of Claims
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Extension of Time Request		
<input type="checkbox"/> Express Abandonment Request		
<input type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
<p>Remarks</p> <p>The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Takeda Pharmaceuticals North America, Inc.		
Signature			
Printed name	Mark Chao		
Date	1/13/08	Reg. No.	37,293

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: *Express*

Signature			
Typed or printed name	Gail L. Winokur	Date	1/13/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mailinq # EV52490706245



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/662,165	Art Unit:	1625
Filed:	09/03/2003	Examiner:	E.Mei Huang
1 st Inventor:	T. Yasuma	Allowed:	
For:	Thienopyridine Derivatives, Their Production and Use	Batch:	
Atty. Dkt. No.	2689 US1P	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524907062 US

DATE IN: January 13, 2005

Itemized Papers/Items:

1. This Certificate and Return Postcard (2 pages)
2. Transmittal Form (1 page X 2)
3. Election of Claims (2 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on this date, 1/13/05

Dated: 1/13/05


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA



1-14-05

IFC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/662,165	Art Unit:	1625
Filed:	09/03/2003	Examiner:	E. Mei Huang
1 st Inventor:	YASUMA, Tsuneo	Allowed:	
For:	Thienopyridine Derivatives, Their Production and Use	Batch:	
Atty. Dkt. No.	2689 US1P	Paper No.:	

Election of Claims

MAIL STOP NON-FEE
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

In response to the Office Action mailed December 16, 2004, Applicants provisionally elect to prosecute Group III, claims 1-18, 23-25, 37 in part, drawn to a compound of formula I, not included in Group I or II, the composition and process of making.

Applicants make the election with traverse. Applicants object to the restriction based upon differentiating Ring B. Applicants believe that the most efficient prosecution of the present case will be accomplished by joining Groups I, II and III and making the restriction between composition and use. Applicants respectfully request the Examiner reconsider the restriction.

Taking by way of example the unity of invention as found for the invention in US Patent 5747486 (cited by the Applicants). The compounds of the general formula I in that patent which were found to be acceptable for unified prosecution, have similar core ring structures as were defined in the present application. The core common structural features of the invention are the Thienopyridine and a Fused Ring B.

As demonstrated by US Patent 5747486, a search conducted by the Office based upon such similar core features, was not unduly burdensome, and the existence of US Patent 5747486 will greatly assist in conducting a search in the present application. Applicant's proposed election defines a group which will allow for efficient, economical prosecution, without undue burden on the Examiner, that will give the applicants an opportunity to pursue claims commensurate with the scope of their disclosure.

No amendment of inventorship is necessitated by this election.

Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully invited to call applicants' attorney at the number below.

Respectfully submitted,



Dated: January 13, 2005

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA